Aarti Pharmalabs Limited has informed the Exchange about change in Management
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs reported audited financial results for FY ended March 2026. Standalone revenue grew marginally to Rs 1,79,755 lakhs from Rs 1,77,135 lakhs, but net profit declined significantly to Rs 17,620 lakhs from Rs 25,735 lakhs (down 31.5%). Basic EPS fell to Rs 19.44 from Rs 28.39. The decline was driven by higher finance costs (doubled to Rs 4,690 lakhs), increased foreign exchange losses of Rs 3,321 lakhs, and a Rs 279 lakh exceptional provision for new labour codes. The company declared a final dividend of Rs 2 per share (40% on Rs 5 face value). Two senior managers - Sachin Patil (Head-Exports) and Rajendra Pagare (Head-Operations & Compliance) - were designated as Senior Management Personnel effective May 25, 2026. Cost and internal auditors were re-appointed for FY27. An unmodified audit opinion was issued.
The 31.5% profit decline despite flat revenue growth signals margin pressure from higher interest and forex costs. The dividend维持 (maintained) at Rs 2 per share provides some investor comfort, but the earnings drop may weigh on the stock near-term.